573 / 1631
RELEVANCE Study Design
(Rituximab and LEnalidomide versus Any ChEmotherapy
•
1,030 patients were enrolled, with 513 in the R
2
arm and 517 in the R-chemo
arm (the control group).
•
Baseline characteristics were similar between the two groups: median age was
59, with 49% men in both groups; approximately 85% of patients had grade 1 or
2 disease, and the remainder had grade 3A disease.
•
The co-primary endpoint—complete remission/complete remission unconfirmed
(CR/Cru)/partial response—was 84% with R
2
versus 89% with R-chemo; SPD
reduction greater than or equal to 50% was reported in 81% of patients in the R
2
group versus 90% in the R-chemo group.